Eventide Asset Management LLC Makes New Investment in Sionna Therapeutics, Inc. $SION

Eventide Asset Management LLC bought a new position in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 639,045 shares of the company’s stock, valued at approximately $26,290,000.

A number of other hedge funds and other institutional investors have also modified their holdings of SION. Goldman Sachs Group Inc. purchased a new stake in shares of Sionna Therapeutics during the first quarter worth about $667,000. Woodline Partners LP purchased a new stake in shares of Sionna Therapeutics during the first quarter worth about $837,000. Geode Capital Management LLC grew its holdings in shares of Sionna Therapeutics by 113.4% during the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after buying an additional 153,712 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Sionna Therapeutics during the second quarter worth about $307,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Sionna Therapeutics during the second quarter worth about $118,000.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock opened at $35.92 on Friday. Sionna Therapeutics, Inc. has a 1 year low of $13.51 and a 1 year high of $48.44. The firm has a 50 day moving average price of $40.09 and a 200 day moving average price of $39.70. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -18.61 and a beta of 1.30.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Sell-side analysts predict that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Peter A. Thompson sold 184,639 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,717,962 shares of company stock valued at $77,571,889. 5.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus lifted their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, May 18th. JonesTrading lifted their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Wedbush assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target for the company. Finally, BTIG Research reiterated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.22.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.